This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Danaher deal for GE biopharma unit gets US FTC approval after company agrees to divest assets

( March 19, 2020, 22:10 GMT | Official Statement) -- MLex Summary: Danaher agreed to divest assets to settle US Federal Trade Commission charges that its deal for General Electric's biopharmaceutical business would violate antitrust law. The FTC said the deal would have substantially reduced competition in the US in 10 highly concentrated product markets. The FTC vote to issue the complaint and accept the settlement was 3-2, with Democratic Commissioners Rohit Chopra and Kelly Slaughter voting no. Statement follows below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login